Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
440 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-01-03
Study Completion Date
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Tuberculosis (TB) is caused by mycobacterial organism. It is the leading infectious disease cause of death globally. According to recent estimates from the World Health Organization (WHO), over 10 million new cases and 1.6 million deaths from TB occurred in 2021. The vast majority of TB cases and TB deaths are in developing countries. Nigeria has the highest TB burden in Africa with a high number of undetected TB cases as well. The spread of HIV has fueled the TB epidemic, and TB is the leading cause of death among patients infected with HIV and has assumed the lead position as the number one infectious disease cause of death globally. Even though the COVID-19 was associated with a huge mortality, TB contributed significantly to death and one of the single predictors of death among COVID-19 infected individuals. TB predominantly affects young adults in their most productive years of life and has substantial impact on economic development.
Emerging evidence has shown that lipid lowering drugs like statins can make the TB bacteria more susceptible to current treatment regimen. The ATORTUB group recently completed Phase II A and Phase IIB studies to assess the safety, tolerability and efficacy of atorvastatin when administered with the current standard of care. The investigators demonstrated that atorvastatin is well tolerated, save, and has beneficial microbiological and radiological impacts in tuberculosis, thus, warrants further studies.
This phase IIC trial sets out to evaluate the safety and efficacy of different doses of atorvastatin containing regimen, determine rate of decline of viable sputum bacilli, the time to stable sputum conversion, improvement in chest ray severity scores and lung function parameters post randomization in the different treatment arms. The phase II C is a Selection Trial with Extended follow-up STEP and has been devised as a pilot phase III where patients are studied for longer period (12months post randomization) than the usual phase IIB. Thus, providing additional data that will justify a successful phase III trial.
Emerging evidence has shown that lipid lowering drugs like statins can make the TB bacteria more susceptible to current treatment regimen. The ATORTUB group recently completed Phase II A and Phase IIB studies to assess the safety, tolerability and efficacy of atorvastatin when administered with the current standard of care. The investigators demonstrated that atorvastatin is well tolerated, save, and has beneficial microbiological and radiological impacts in tuberculosis, thus, warrants further studies.
This phase IIC trial sets out to evaluate the safety and efficacy of different doses of atorvastatin containing regimen, determine rate of decline of viable sputum bacilli, the time to stable sputum conversion, improvement in chest ray severity scores and lung function parameters post randomization in the different treatment arms. The phase II C is a Selection Trial with Extended follow-up STEP and has been devised as a pilot phase III where patients are studied for longer period (12months post randomization) than the usual phase IIB. Thus, providing additional data that will justify a successful phase III trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct
NCT04504851
Pulmonary Tuberculosis
UNKNOWN
PHASE2
Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis
NCT03160638
Tuberculosis, Pulmonary
COMPLETED
PHASE2
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
NCT02581527
Pulmonary Tuberculosis
COMPLETED
PHASE3
A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis
NCT00216385
Tuberculosis
UNKNOWN
PHASE3
Tuberculosis Prevention for HIV Infected Adults
NCT00057122
HIV Infections
Tuberculosis
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
INTRODUCTION Tuberculosis is a chronic disease responsible for most deaths from infectious disease with an estimated I0 million cases and close to 2 million deaths globally. Despite the availability of therapy for TB, the scourge of the disease has not abated especially in the developing countries. The disease is caused by a bacterium called Mycobacterium tuberculosis, a non-spore forming intracellular organism. TB exists in two forms; primary and secondary infection. While primary infection most times goes unnoticed and are usually associated with non-specific symptoms, secondary infections are usually associated with profound symptoms and signs in various organs especially in the lungs. Majority of persons overcome primary infection but the tubercule bacilli may lie dormant in the macrophages. Secondary infection occurs as a result of either endogenous reactivation or exogenous re-infection. Pulmonary TB is responsible for more than 85% of the cases.
MTB infect and survive humans by evading the various immune defense systems. The organism accumulates and utilizes an abundant amount of lipids and cholesterol for its cell wall, and as a source of carbon for synthesis of virulence factors. Mycobacterium tuberculosis also utilizes cholesterol as a vehicle to enter macrophage, inhibit phagocytosis and inhibit growth and development of phagocytes. These greatly impairs the hydrolytic and antimicrobial properties and activities of phagocytes. Current therapy is as old as the disease itself; is of long duration, hence it is associated with poor compliance. This contributes to frequent relapses and emergence of resistant form of the disease. Average interval between one episode of TB and another ranges from 6-18 months after completion of therapy. Despite clinical cure, approximately half of patients have permanent lung damage. In Nigeria, TB is a major risk factor for Chronic Obstructive Pulmonary Disease, lung fibrosis/scarring and other diseases. It is clear that new and innovative therapeutic agents are needed to tackle this hydra- headed disease. In order to address these challenges, a lipid lowering agent, atorvastatin is being repurposed.
The use of statins have been demonstrated in infectious diseases and especially in tuberculosis than other organisms. In vitro studies have demonstrated that statins could strengthen the host response against M. tuberculosis and inhibit the activation of T cells induced by M. tuberculosis antigens. In another study, murine bone marrow-derived macrophages that were exposed to simvastatin and were infected with M. tuberculosis, showed a significant reduction in mycobacterial growth, without adverse effects on cell viability. Treatment of TB in animal model with statins and anti TB drugs showed that treatment with anti-TB drugs plus simvastatin reduced the percentage of relapses by 50% compared with treatment with only anti-TB drugs. Taken together, all these studies in animal model indicate that statins has anti-TB effect, reduces bacillary load, shortens the duration of therapy and decreases relapse rate when used with first-line anti-TB drugs.
Most of the clinical evidence on the role of statins in TB were from retrospective and nested case control studies from Asian continent. In one study in Taiwan, diabetic subjects older than 65 treated with statins had a lower risk of developing active tuberculosis, with a risk of 0.76 (95% CI, 0.60-0.97). Chronic use of statins (more than 90 days) was associated with the lowest risk (RR 0.62; 95% CI 0.53-0.72) as shown in another study.
The ATORTUB investigators recently completed two phase 2 studies to assess the safety, tolerability and efficacy of atorvastatin administered with the current standard of care. The first study was a phase IIA study involving 40 patients randomized to receive standard of care alone and standard of care with oral (40mg) dose atorvastatin. Primary outcome at 2 weeks was safety, tolerability and early bactericidal activity over a 2 week period. The study showed that atorvastatin was generally safe and well tolerated. The rate of decline of colony forming unit was higher among the atorvastatin group. Even though there was no early bactericidal activity demonstrated at 2 weeks, atorvastatin group had significantly number of participants with more than 0.5 log10 decline in colony forming unit. This was quite significant. At the phase IIB study, 150 eligible participant's were randomly assigned to either of the two arms. All the participants had rifampicin sensitive active non complicated TB. Other drug resistance testing were not done. Oral dose of 40mg of atorvastatin was given for 2 months together with standard of care drugs and afterwards the standard of care drugs were continued for the patients to complete 6 months of therapy. Primary outcome were safety and tolerability atorvastatin , efficacy measured by the number of sputum conversion at 2 months. Secondary outcome was chest x-ray severity score at 2 months. AT the end of the phase IIB trial, it was shown that atorvastatin was generally safe and in fact participants in that group had reduced incidence of peripheral neuropathy. More participants achieved sputum conversion compared with the standard of care group. The mean improvement in chest x-ray severity score was higher in the experimental group Atorvastatin in combination with standard antituberculosis drugs achieved a significantly higher rate of sputum culture negativity and reduction in mycobacterial burden in sputum at 2 months compared with antituberculosis drugs alone. The difference in sputum negativity and the mean fall in colony forming unit per ml of sputum per month were significantly higher among the intervention group. The use of atorvastatin was also significantly associated with a negative sputum result. These may be indicative of the anti-mycobactericidal effect of atorvastatin, which had been earlier reported in murine models, other invitro studies and consistent with the earlier phase IIA result .
The ATORTUB investigators therefore concluded that atorvastatin has beneficial microbiological and radiological impacts in tuberculosis and warrants further studies.
Though, the phase IIB study reported positive findings that suggests the beneficial role of atorvastatin, however, before moving to a more expensive phase III study, important information relating to the clinical trial needs to be answered. For example, there is a need to establish the time to stable sputum conversion. This will be useful in determining the effective duration of atorvastatin containing regimen. In addition, evaluating the regimen among unbiased and diverse groups of patients including those with HIV, DM, hypertension and possibly children will be helpful and required. Even though, the dose we used was effective, conducting pk-pd evaluations at different doses and correlating these with outcomes of the trial will be essential.
Phase IIC also referred to as Selection Trial with Extended follow-up STEP, has been devised as a pilot phase III where patients are studied for longer period than the usual phase IIB and additional data that will justify and ensure a successful phase III trial are obtained. Patients are followed up for a fairly longer time in phase IIC , 12 months post randomization.
2\. Study Design
Experimental design/Research Plan This is a multicenter, randomized, controlled, open-label, 4-arm, phase IIC superiority trial.
For the phase III aspect, the study will be fully international and multicenter.
Phase IIC will seek to determine the safety and efficacy of different doses of atorvastatin containing regimen , the time to sputum culture conversion, time to decline in Chest x-ray severity score and improvement in lung function parameters by atorvastatin at mentioned doses in combination with standard anti-TB regimen in 440 patients.
Consented and eligible patients aged12 -65 years with active tuberculosis will be recruited and have study-specific procedures initiated at enrollment / Screening visit. At screening visit, participants will be interviewed for demographics, contact information, medical history. They will have their anthropometry documented, will be screened for HIV, Diabetes and Pregnancy (in females), and have sputum collected for mycobacterial smear and culture.
At baseline visit (visit at which study drug is initiated), sputum will be collected for mycobacterial smear and culture, blood sample for complete blood count, serum or plasma for alanine aminotransferase (ALT), total bilirubin, creatinine, albumin, and potassium, complete lipid profile, creatine phosphokinase, unless results from those tests performed within fourteen days prior to screening are available. Sweat test and lung function test will be performed prior randomization. In this visit (baseline), participants will be randomized to receive either 20/40/60mg of daily treatment with atorvastatin for 16 weeks (from the beginning of standard of care treatment) with standard anti-TB regimen (2RHZE/4RH) for 24weeks (6 months) or the standards anti-TB drugs alone for 24 weeks (6 months). Randomization will be stratified by site, by HIV status (HIV-uninfected vs. HIV- infected with CD4 T cell count greater than or equal to 200 cells/mm3 vs. HIV-infected with CD4 T cell count less than 200 cells/mm3) and by DM status (DM patients vs. non-DM) and will follow a predefined allocation ratio of 1:1:1:1. Thereafter, participants will be followed up closely up to 12 months post randomization (i.e. study specific procedures will be carried out at weeks 2,4,6,8,10,12, 16, 22, 24; months 8, 10 and 12 post randomization according to study protocol). During this period, the number and types of Adverse Events in the participants will also be reported and documented.
MTB infect and survive humans by evading the various immune defense systems. The organism accumulates and utilizes an abundant amount of lipids and cholesterol for its cell wall, and as a source of carbon for synthesis of virulence factors. Mycobacterium tuberculosis also utilizes cholesterol as a vehicle to enter macrophage, inhibit phagocytosis and inhibit growth and development of phagocytes. These greatly impairs the hydrolytic and antimicrobial properties and activities of phagocytes. Current therapy is as old as the disease itself; is of long duration, hence it is associated with poor compliance. This contributes to frequent relapses and emergence of resistant form of the disease. Average interval between one episode of TB and another ranges from 6-18 months after completion of therapy. Despite clinical cure, approximately half of patients have permanent lung damage. In Nigeria, TB is a major risk factor for Chronic Obstructive Pulmonary Disease, lung fibrosis/scarring and other diseases. It is clear that new and innovative therapeutic agents are needed to tackle this hydra- headed disease. In order to address these challenges, a lipid lowering agent, atorvastatin is being repurposed.
The use of statins have been demonstrated in infectious diseases and especially in tuberculosis than other organisms. In vitro studies have demonstrated that statins could strengthen the host response against M. tuberculosis and inhibit the activation of T cells induced by M. tuberculosis antigens. In another study, murine bone marrow-derived macrophages that were exposed to simvastatin and were infected with M. tuberculosis, showed a significant reduction in mycobacterial growth, without adverse effects on cell viability. Treatment of TB in animal model with statins and anti TB drugs showed that treatment with anti-TB drugs plus simvastatin reduced the percentage of relapses by 50% compared with treatment with only anti-TB drugs. Taken together, all these studies in animal model indicate that statins has anti-TB effect, reduces bacillary load, shortens the duration of therapy and decreases relapse rate when used with first-line anti-TB drugs.
Most of the clinical evidence on the role of statins in TB were from retrospective and nested case control studies from Asian continent. In one study in Taiwan, diabetic subjects older than 65 treated with statins had a lower risk of developing active tuberculosis, with a risk of 0.76 (95% CI, 0.60-0.97). Chronic use of statins (more than 90 days) was associated with the lowest risk (RR 0.62; 95% CI 0.53-0.72) as shown in another study.
The ATORTUB investigators recently completed two phase 2 studies to assess the safety, tolerability and efficacy of atorvastatin administered with the current standard of care. The first study was a phase IIA study involving 40 patients randomized to receive standard of care alone and standard of care with oral (40mg) dose atorvastatin. Primary outcome at 2 weeks was safety, tolerability and early bactericidal activity over a 2 week period. The study showed that atorvastatin was generally safe and well tolerated. The rate of decline of colony forming unit was higher among the atorvastatin group. Even though there was no early bactericidal activity demonstrated at 2 weeks, atorvastatin group had significantly number of participants with more than 0.5 log10 decline in colony forming unit. This was quite significant. At the phase IIB study, 150 eligible participant's were randomly assigned to either of the two arms. All the participants had rifampicin sensitive active non complicated TB. Other drug resistance testing were not done. Oral dose of 40mg of atorvastatin was given for 2 months together with standard of care drugs and afterwards the standard of care drugs were continued for the patients to complete 6 months of therapy. Primary outcome were safety and tolerability atorvastatin , efficacy measured by the number of sputum conversion at 2 months. Secondary outcome was chest x-ray severity score at 2 months. AT the end of the phase IIB trial, it was shown that atorvastatin was generally safe and in fact participants in that group had reduced incidence of peripheral neuropathy. More participants achieved sputum conversion compared with the standard of care group. The mean improvement in chest x-ray severity score was higher in the experimental group Atorvastatin in combination with standard antituberculosis drugs achieved a significantly higher rate of sputum culture negativity and reduction in mycobacterial burden in sputum at 2 months compared with antituberculosis drugs alone. The difference in sputum negativity and the mean fall in colony forming unit per ml of sputum per month were significantly higher among the intervention group. The use of atorvastatin was also significantly associated with a negative sputum result. These may be indicative of the anti-mycobactericidal effect of atorvastatin, which had been earlier reported in murine models, other invitro studies and consistent with the earlier phase IIA result .
The ATORTUB investigators therefore concluded that atorvastatin has beneficial microbiological and radiological impacts in tuberculosis and warrants further studies.
Though, the phase IIB study reported positive findings that suggests the beneficial role of atorvastatin, however, before moving to a more expensive phase III study, important information relating to the clinical trial needs to be answered. For example, there is a need to establish the time to stable sputum conversion. This will be useful in determining the effective duration of atorvastatin containing regimen. In addition, evaluating the regimen among unbiased and diverse groups of patients including those with HIV, DM, hypertension and possibly children will be helpful and required. Even though, the dose we used was effective, conducting pk-pd evaluations at different doses and correlating these with outcomes of the trial will be essential.
Phase IIC also referred to as Selection Trial with Extended follow-up STEP, has been devised as a pilot phase III where patients are studied for longer period than the usual phase IIB and additional data that will justify and ensure a successful phase III trial are obtained. Patients are followed up for a fairly longer time in phase IIC , 12 months post randomization.
2\. Study Design
Experimental design/Research Plan This is a multicenter, randomized, controlled, open-label, 4-arm, phase IIC superiority trial.
For the phase III aspect, the study will be fully international and multicenter.
Phase IIC will seek to determine the safety and efficacy of different doses of atorvastatin containing regimen , the time to sputum culture conversion, time to decline in Chest x-ray severity score and improvement in lung function parameters by atorvastatin at mentioned doses in combination with standard anti-TB regimen in 440 patients.
Consented and eligible patients aged12 -65 years with active tuberculosis will be recruited and have study-specific procedures initiated at enrollment / Screening visit. At screening visit, participants will be interviewed for demographics, contact information, medical history. They will have their anthropometry documented, will be screened for HIV, Diabetes and Pregnancy (in females), and have sputum collected for mycobacterial smear and culture.
At baseline visit (visit at which study drug is initiated), sputum will be collected for mycobacterial smear and culture, blood sample for complete blood count, serum or plasma for alanine aminotransferase (ALT), total bilirubin, creatinine, albumin, and potassium, complete lipid profile, creatine phosphokinase, unless results from those tests performed within fourteen days prior to screening are available. Sweat test and lung function test will be performed prior randomization. In this visit (baseline), participants will be randomized to receive either 20/40/60mg of daily treatment with atorvastatin for 16 weeks (from the beginning of standard of care treatment) with standard anti-TB regimen (2RHZE/4RH) for 24weeks (6 months) or the standards anti-TB drugs alone for 24 weeks (6 months). Randomization will be stratified by site, by HIV status (HIV-uninfected vs. HIV- infected with CD4 T cell count greater than or equal to 200 cells/mm3 vs. HIV-infected with CD4 T cell count less than 200 cells/mm3) and by DM status (DM patients vs. non-DM) and will follow a predefined allocation ratio of 1:1:1:1. Thereafter, participants will be followed up closely up to 12 months post randomization (i.e. study specific procedures will be carried out at weeks 2,4,6,8,10,12, 16, 22, 24; months 8, 10 and 12 post randomization according to study protocol). During this period, the number and types of Adverse Events in the participants will also be reported and documented.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pulmonary Tuberculosis
Tuberculosis
Koch's Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
20mg atorvastatin with standard of care (SOC) for TB
Trial of 20mg atorvastatin with standard of care (SOC) for TB
Group Type
EXPERIMENTAL
Atorvastatin 20mg
Intervention Type
DRUG
Participants will receive oral atorvastatin 20mg daily for 16 weeks
40mg atorvastatin with standard of care (SOC) for TB
Trial of 40mg atorvastatin with standard of care (SOC) for TB
Group Type
EXPERIMENTAL
Atorvastatin 40mg
Intervention Type
DRUG
Participants will receive oral atorvastatin 40mg daily for 16 weeks
60mg atorvastatin with standard of care (SOC) for TB
Trial of 60mg atorvastatin with standard of care (SOC) for TB
Group Type
EXPERIMENTAL
Atorvastatin 60mg
Intervention Type
DRUG
Participants will receive oral atorvastatin 60 mg daily for 16 weeks
Standard of care (SOC) for TB
Standard of care (SOC) for TB
Group Type
ACTIVE_COMPARATOR
Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
Intervention Type
DRUG
Participants will receive 8 weeks of daily oral treatment with rifampin, isoniazid, pyrazinamide, ethambutol, followed by 16 weeks of daily oral treatment with rifampin, isoniazid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin 20mg
Participants will receive oral atorvastatin 20mg daily for 16 weeks
Intervention Type
DRUG
Atorvastatin 40mg
Participants will receive oral atorvastatin 40mg daily for 16 weeks
Intervention Type
DRUG
Atorvastatin 60mg
Participants will receive oral atorvastatin 60 mg daily for 16 weeks
Intervention Type
DRUG
Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
Participants will receive 8 weeks of daily oral treatment with rifampin, isoniazid, pyrazinamide, ethambutol, followed by 16 weeks of daily oral treatment with rifampin, isoniazid
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Astin
Astin
Astin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
A. Suspected pulmonary tuberculosis plus one or both of the following: a) at least one sputum specimen positive for acid-fast bacilli on smear microscopy OR b) at least one sputum specimen positive for M. tuberculosis by Xpert MTB/RIF testing, with semiquantitative result of 'medium' or 'high' and rifampicin resistance not detected.
B. Treatment naive
C. Age twelve years or older
D. A verifiable address or residence location that is readily accessible for visiting, and willingness to inform the study team of any change of address during the treatment and follow-up period.
E. Documented HIV infection status.
F. Documented blood sugar level/ Diabetes
G. For HIV-positive individuals, CD4 T cell count greater than or equal to 100 cells/mm3 based on testing performed at or within 30 days prior to screening.
H. Laboratory parameters done at or within 14 days prior to screening:
* Serum or plasma alanine aminotransferase (ALT) less than or equal to 3 times the upper limit of normal
* Serum or plasma total bilirubin less than or equal to 2.5 times the upper limit of normal
* Serum or plasma creatinine level less than or equal to 2 times the upper limit of normal
* Serum or plasma potassium level greater than or equal to 3.5 meq/L
* Hemoglobin level of 7.0 g/dL or greater
* Platelet count of 100,000/mm3 or greater
I. For women of childbearing potential, a negative pregnancy test at or within seven (7) days prior to screening
J. Written informed consent
B. Treatment naive
C. Age twelve years or older
D. A verifiable address or residence location that is readily accessible for visiting, and willingness to inform the study team of any change of address during the treatment and follow-up period.
E. Documented HIV infection status.
F. Documented blood sugar level/ Diabetes
G. For HIV-positive individuals, CD4 T cell count greater than or equal to 100 cells/mm3 based on testing performed at or within 30 days prior to screening.
H. Laboratory parameters done at or within 14 days prior to screening:
* Serum or plasma alanine aminotransferase (ALT) less than or equal to 3 times the upper limit of normal
* Serum or plasma total bilirubin less than or equal to 2.5 times the upper limit of normal
* Serum or plasma creatinine level less than or equal to 2 times the upper limit of normal
* Serum or plasma potassium level greater than or equal to 3.5 meq/L
* Hemoglobin level of 7.0 g/dL or greater
* Platelet count of 100,000/mm3 or greater
I. For women of childbearing potential, a negative pregnancy test at or within seven (7) days prior to screening
J. Written informed consent
Exclusion Criteria
A. Pregnant or breast-feeding
B. Unable to take oral medications
C. Those already on treatment for tuberculosis
D. Weight less than 40.0 kg
E. Known allergy or intolerance to any of the study medications
F. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of the following: rifampin, isoniazid, pyrazinamide,or ethambutol,
G. .Evidence of clinically significant metabolic or co morbid medical conditions ; malignancy; or other diseases like history of or current cardiovascular disorder such as heart failure, coronary heart disease, arrhythmia.
H. Known or family history of bleeding disorders. I. Any renal impairment characterized by serum creatinine clearance of 1.5 x upper limit of normal of the clinical laboratory reference range at screening.
J. Myositis and or Creatinine phosphokinase three times upper limit of normal K. Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest.
Criteria for Exclusion after Enrollment ('Late Exclusion')
Microbiological confirmation of drug-susceptible tuberculosis is not expected always to be available at the time of enrollment. Enrolled individuals who are subsequently determined to meet either of the following criteria will be classified as 'late exclusions' and study treatment will be discontinued:
A. Screening, baseline, and Week 2 study visit sputum cultures all fail to grow M. tuberculosis.
B. M. tuberculosis cultured or detected through molecular assays (Cepheid Xpert MTB/RIF or Hain MTBDRplus assays) from sputum obtained around the time of study entry is determined to be resistant to one or more of isoniazid, rifampin, or fluoroquinolones.
B. Unable to take oral medications
C. Those already on treatment for tuberculosis
D. Weight less than 40.0 kg
E. Known allergy or intolerance to any of the study medications
F. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of the following: rifampin, isoniazid, pyrazinamide,or ethambutol,
G. .Evidence of clinically significant metabolic or co morbid medical conditions ; malignancy; or other diseases like history of or current cardiovascular disorder such as heart failure, coronary heart disease, arrhythmia.
H. Known or family history of bleeding disorders. I. Any renal impairment characterized by serum creatinine clearance of 1.5 x upper limit of normal of the clinical laboratory reference range at screening.
J. Myositis and or Creatinine phosphokinase three times upper limit of normal K. Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest.
Criteria for Exclusion after Enrollment ('Late Exclusion')
Microbiological confirmation of drug-susceptible tuberculosis is not expected always to be available at the time of enrollment. Enrolled individuals who are subsequently determined to meet either of the following criteria will be classified as 'late exclusions' and study treatment will be discontinued:
A. Screening, baseline, and Week 2 study visit sputum cultures all fail to grow M. tuberculosis.
B. M. tuberculosis cultured or detected through molecular assays (Cepheid Xpert MTB/RIF or Hain MTBDRplus assays) from sputum obtained around the time of study entry is determined to be resistant to one or more of isoniazid, rifampin, or fluoroquinolones.
Minimum Eligible Age
12 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Open Philanthropy
OTHER
Sponsor Role
collaborator
Obafemi Awolowo University Teaching Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adewole Olufemi
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olanisun O Adewole, MD
Role: PRINCIPAL_INVESTIGATOR
Obafemi Awolowo University /Teaching Hospital, Ile- Ife, Osun State, Nigeria
Olanisun O Adewole, MD
Role: STUDY_CHAIR
Obafemi Awolowo University/ Teaching Hospital, Ile- Ife, Osun State, Nigeria
Bolanle A Omotoso, MD
Role: STUDY_DIRECTOR
Obafemi Awolowo University/ Teaching Hospital, Ile- Ife, Osun State, Nigeria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Tuberculosis Reference Laboratory
Zaria, Kaduna State, Nigeria
Site Status
RECRUITING
Federal Teaching Hospital
Katsina, Katsina State, Nigeria
Site Status
RECRUITING
Federal Medical Center
Keffi, Nasarawa State, Nigeria
Site Status
RECRUITING
Obafemi Awolowo University Teaching Hospitals Complex
Ile-Ife, Osun State, Nigeria
Site Status
RECRUITING
Bowen University Teaching Hospital
Iwo, Osun State, Nigeria
Site Status
RECRUITING
University College Hospital
Ibadan, Oyo State, Nigeria
Site Status
RECRUITING
Usman Danfodio University
Sokoto, Sokoto State, Nigeria
Site Status
RECRUITING
University of Abuja Teaching Hospital
Gwagwalada, , Nigeria
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Nigeria
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eunice Jiya
Role: primary
+2348033714310
Taofeek Oloyede
Role: primary
Modupe Ogunsina, Dr
Role: primary
Olufemi Adewole, MD
Role: primary
Abiona Odeyemi, MD
Role: primary
+2347032512473
Olumide Sogaolu, MD
Role: primary
+234
Aminu Abbas
Role: primary
+2348035776419
Alex Akor, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB/IEC/0004553
Identifier Type: OTHER
Identifier Source: secondary_id
ERC/2023/11/15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Tuberculosis Treatment Shortening Trial
NCT00130247
COMPLETED
PHASE3
Biomarkers for Therapy Response in Drug-resistant Tuberculosis
NCT02597621
COMPLETED
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
NCT02410772
COMPLETED
PHASE3
Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response
NCT03416309
UNKNOWN
Efficacy and Safety of Intravenous Treatment of Tuberculosis
NCT04150367
TERMINATED
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)
NCT00944021
COMPLETED
PHASE2
Phase 2a EBA Trial of AZD5847
NCT01516203
COMPLETED
PHASE2
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
NCT07163143
NOT_YET_RECRUITING
PHASE3
Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB
NCT01392911
COMPLETED
PHASE2
Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
NCT03545373
COMPLETED
PHASE3
Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana
NCT00164281
COMPLETED
PHASE4
Evaluation of PATHFAST-LAM as a Tuberculosis Treatment Monitoring Tool in Kenya
NCT07157904
NOT_YET_RECRUITING
Novel Triple-dose Tuberculosis Retreatment Regimen
NCT04260477
RECRUITING
PHASE3
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
NCT05401071
RECRUITING
PHASE2/PHASE3
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
NCT04930978
RECRUITING
A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients
NCT06021041
UNKNOWN
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761
RECRUITING
PHASE3
Statin Adjunctive Therapy for TB
NCT03456102
COMPLETED
PHASE2
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
NCT06081361
ACTIVE_NOT_RECRUITING
PHASE3
Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis
NCT00698334
COMPLETED
PHASE3
An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis
NCT03557281
COMPLETED
PHASE2
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
NCT06114628
RECRUITING
PHASE2
StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
NCT03882177
COMPLETED
PHASE2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
NCT03474029
RECRUITING
PHASE2/PHASE3
DIAgnostics for Multidrug Resistant Tuberculosis in Africa
NCT03303963
COMPLETED